Profiling bortezomib resistance identifies secondary therapies in a mouse myeloma model.
Stessman HA, Baughn LB, Sarver A, Xia T, Deshpande R, Mansoor A, Walsh SA, Sunderland JJ, Dolloff NG, Linden MA, Zhan F, Janz S, Myers CL, Van Ness BG.
Stessman HA, et al. Among authors: janz s.
Mol Cancer Ther. 2013 Jun;12(6):1140-50. doi: 10.1158/1535-7163.MCT-12-1151. Epub 2013 Mar 27.
Mol Cancer Ther. 2013.
PMID: 23536725
Free PMC article.